Why Starbox Group Shares Are Trading Higher By 22%; Here Are 20 Stocks Moving Premarket
Benzinga · 01/19 12:48
Why Calyxt Shares Are Trading Higher By Around 116%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Benzinga · 01/17 18:21
BRIEF-AIM Immuno Tech Enters Into Pancreatic Cancer Research Agreements With Astrazeneca And Erasmus Medical Center
Reuters · 01/17 18:19
AIM ImmunoTech gains on research deal for lead asset
Seeking Alpha · 01/17 16:04
AIM ImmunoTech Enters Into Pancreatic Cancer Clinical Research Agreements With AstraZeneca And Erasmus Medical Center
Benzinga · 01/17 13:50
Why First Wave BioPharma Shares Are Trading Higher By 23%; Here Are 20 Stocks Moving Premarket
Benzinga · 01/17 12:52
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Investor Place · 01/17 12:33
Why Lightning eMotors Shares Are Trading Lower By 9%; Here Are 20 Stocks Moving Premarket
Benzinga · 01/11 12:58
BRIEF-Aim Immunotech Broadens Patent Portfolio With New Netherlands Utility Patent Covering Ampligen® And Other Aim-Developed Dsrna Products To Include Rugged Dsrna For Use In Covid-19 Treatment Or Prevention
Reuters · 01/09 13:35
AIM ImmunoTech, InnSuites Hospitality Trust And 2 Other Penny Stocks Insiders Are Aggressively Buying
Benzinga · 01/05 14:40
Why Enovix Shares Are Trading Lower By 43%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Benzinga · 01/04 18:17
AIM ImmunoTech's Return On Capital Employed Insights
Benzinga · 12/28/2022 14:46
Why Innate Pharma Shares Are Trading Higher By 24%; Here Are 34 Stocks Moving Premarket
Benzinga · 12/19/2022 11:13
BRIEF-AIM ImmunoTech Reports Positive Data For Intranasal Ampligen (Rintatolimod)
Reuters · 12/08/2022 14:07
AIM ImmunoTech Reports Safety, Tolerability And Biological Activity Data For Intranasal Ampligen In Healthy Subjects
Benzinga · 12/08/2022 13:08
AIM ImmunoTech Announces Abstract Accepted For Poster Presentation At British Society For Immunology Congress 2022 Dec. 7
Benzinga · 12/02/2022 15:46
AIM ImmunoTech GAAP EPS of -$0.13 misses by $0.01
Seekingalpha · 11/15/2022 12:39
BRIEF-Aim Immunotech Reports Third Quarter 2022 Financial Results
Reuters · 11/15/2022 12:12
AIM ImmunoTech Q3 EPS $(0.13) Down From $(0.08) YoY
Benzinga · 11/15/2022 12:07
AIM ImmunoTech Announces Presentation of New Data from Roswell Park Comprehensive Cancer Center Evaluating Ampligen® as a Component of a Chemokine-Modulating (CKM) Regimen, with Paclitaxel, for the Treatment of Early-Stage Triple Negative Breast Cancer
– Data selected for poster presentation at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting – Treatment was well tolerated, with promising clinical activity of pathologic complete response (pCR) + microinvasive residual disease (ypTmic) a...
GlobeNewswire · 11/14/2022 12:00
Webull provides a variety of real-time AIM stock news. You can receive the latest news about Aim Immunotech through multiple platforms. This information may help you make smarter investment decisions.
About AIM
AIM ImmunoTech Inc. is an immuno-pharmaceutical company. The Company is focused on the research and development of therapeutics to treat multiple types of cancers, viral diseases and immune-deficiency disorders. The Company’s flagship products are Ampligen (rintatolimod), a drug of large macromolecular ribonucleic acid (RNA) molecules, and Alferon N Injection (Interferon Alfa-N3). Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe chronic fatigue syndrome (CFS) and is an experimental drug in the United States undergoing clinical development for the treatment of certain cancers and ME/CFS. Alferon N Injection is the registered trademark for its injectable formulation of natural alpha interferon. Alferon N Injection is a natural-source, multi-species alpha interferon approved for sale in the United States and Argentina for the intralesional treatment of refractory or recurring external genital warts in patients 18 years of age or older.